BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Status:
Completed
Trial end date:
2021-06-26
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ubidecarenone injectable
nanosuspension (BPM31510) in treating patients with high-grade glioma (anaplastic astrocytoma
or glioblastoma) that has come back and have been previously treated with bevacizumab.
BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.